{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.5","upperLimit":"2.8","value":"2.3"},{"groupId":"OG001","lowerLimit":"3.4","upperLimit":"7.7","value":"4.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"18"}],"units":"Participants"}],"description":"Time to Progression (TTP):date of first infusion to the date of documented progressive disease which can be defined as \\>25 percentage increase in level of serum monoclonal paraprotein.","dispersionType":"Full Range","groups":[{"description":"Plitidepsin 5 mg/m2 given as a 3-hour i.v. infusion every two weeks.","id":"OG000","title":"Plitidepsin"},{"description":"Plitidepsin 5 mg/m2 given as a 3-hour i.v. infusion every two weeks plus 20 mg of oral dexamethasone every day on days 1 to 4 of each cycle, starting at the same time than the plitidepsin infusion.","id":"OG001","title":"Plitidepsin + Dexamethasone"}],"paramType":"MEDIAN","populationDescription":"Per protocol - Only 29 of 32 and 18 of 19 enrolled patients were evaluable (analyzed patients)","reportingStatus":"POSTED","timeFrame":"Every 2 weeks until progression or death due to progression occurs. Median TTP and TTP rates at 3 months and 6 months were assessed.","title":"Time to Progression (TTP)","type":"SECONDARY","unitOfMeasure":"months"}